Survey to Assess Why People Are Not Responding to Treatment in Hypertension
- Registration Number
- NCT01071681
- Lead Sponsor
- Bayer
- Brief Summary
This study will describe the factors influencing the physician in face of elevated blood pressure in already treated patients
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1589
Inclusion Criteria
- Men or women over 18
- Hypertensive patients
- Uncontrolled hypertension (blood pressure >/=140/90 mmHg on the day of consultation or >/=130/80 mmHg in diabetic patients or in patients suffering from kidney failure, or in elderly patients with a systolic blood pressure >/=150 mmHg (in the absence of orthostatic hypotension)
- Patients treated with a combination, fixed or not, of Renin-Angiotensin System Blocker (RASB) + Hydrochlorothiazide (HCTZ)
- Patients examined in common medical care practice, whatever the reason for consultation
- Patients informed of the study
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Group 1 Telmisartan (Kinzal/Pritor, BAY68-9291) -
- Primary Outcome Measures
Name Time Method Percentage of patients, according to the level of cardiovascular risk, who, at the end of the visit:- do not present any modification of hypertension treatment (therapeutic inertia) - present a change in the hypertension therapeutic on day 1
- Secondary Outcome Measures
Name Time Method Analyses of the factors that had an impact on the therapeutic decision on day 1